Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $500
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Eli Lilly (NYSE:LLY) and raises the price target from $440 to $500.
May 26, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo maintains an Overweight rating on Eli Lilly and raises the price target from $440 to $500.
The news of Wells Fargo maintaining an Overweight rating on Eli Lilly and raising the price target from $440 to $500 indicates a positive outlook for the company's stock. This could lead to an increase in investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100